Abraxis BioScience Announces Approval To Market ABRAXANE For Metastatic Breast Cancer In China
Jul 16th 2008Drug InformationBreast Cancer
Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated biotechnology company, announced it has received approval from the China State Food and Drug Administration to market ABRAXANEŽ Paclitaxel for Injection (Albumin Bound) for the treatment of breast cancer after failure of standard chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. The Phase III clinical trials in the U.S.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
